Abstract
Objective To investigate the therapeutic efficacy and safety of neoadjuvant chemotherapy of paclitaxel plus carboplatin for advanced epithelial ovarian cancer. Methods Forty-six patients with advanced epithelial ovarian cancer（ treatment group ）were treated by neoadjuvant chemotherapy of paclitaxel 135-175 mg/m2 plus carboplatin AUC=6,paclitaxel was given on the 1st day,carboplatin was given on day 1-5,21 days for a cycle,and treatment for 3 cycles. Previous forty-five cases of advanced epithelial ovarian cancer（ control group）were treated by neoadjuvant chemotherapy of cyclophosphamide 500-750 mg/m2 plus cisplatin 75 mg/m2 ,cyclophosphamide was given on the 1st day,carboplatin was given on day 1-3,21 days for a cycle,and treatment for 3 cycles. The therapeutic efficacy and toxicity in two groups were evaluated. Results The treatment group was superior to the control group in the effective rate,disease control rate,resection rate of metra and appendix,and satisfactory cytoreductive surgery rate（P﹤0. 05）. The main side effects were hematologic toxicities and gastrointestinal response,but they were tolerable,and there was no death related with treatment. No severely harmful actions were found. Conclusions Neoadjuvant chemotherapy of paclitaxel plus carboplatin for advanced epithelial ovarian cancer is a highly effective method for advanced epithelial ovarian cancer,and the toxicity is tolerable. Key words: Paclitaxel; Carboplatin; Advanced epithelial ovarian cancer; Neoadjuvant chemotherapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
